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Abstract
Lafora disease is the most common teenage-onset neurodegenerative disease, the main teenage-onset form of progressive
myoclonus epilepsy (PME), and one of the severest epilepsies. Pathologically, a starch-like compound, polyglucosan,
accumulates in neuronal cell bodies and overtakes neuronal small processes, mainly dendrites. Polyglucosan formation is
catalyzed by glycogen synthase, which is activated through dephosphorylation by glycogen-associated protein
phosphatase-1 (PP1). Here we remove PTG, one of the proteins that target PP1 to glycogen, from mice with Lafora
disease. This results in near-complete disappearance of polyglucosans and in resolution of neurodegeneration and
myoclonic epilepsy. This work discloses an entryway to treating this fatal epilepsy and potentially other glycogen storage
diseases.
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Introduction
Lafora disease (LD) is caused by recessively inherited
mutations in the EPM2A or EPM2B genes, encoding laforin (a
carbohydrate binding phosphatase) and malin (an E3 ubiquitin
ligase) [1,2]. The disease begins around age 15 with myoclonus
(jerk-like seizures) and generalized convulsive seizures, which
initially respond to medications. Over the next five years
seizures become intractable and the myoclonus near-constant,
and epileptic hallucinations with highly frightening content
appear. Extremely frequent myoclonic seizures (repetitive jerks)
and epileptic absence attacks permeate consciousness and
prevent formulation of complete thoughts. Dementia and a
vegetative state in constant myoclonus follow. Death occurs
around age 25 in status epilepticus. Pathology consists of the
progressive formation of polyglucosans, which are insoluble
glucose polysaccharides that precipitate and aggregate into
concretized masses called Lafora bodies (LB), and in neurode-
generation. LB form in neuronal perikarya (i.e. in the cell body
near the nucleus) and in neuronal short processes (mostly
dendrites). LB in the neuronal processes are much smaller but
they massively outnumber LB in the perikarya. Extraneurally,
LB also form in heart, liver, and skeletal muscle, but cause no
symptoms in these organs [3–6].
A normal glycogen molecule contains up to 55,000 glucose
units, yet remains soluble because its glucose chains are short (13
units), each chain is a branch of another, and the whole molecule
is a sphere, the surface of which is composed of the hydrophilic
ends of chains [7]. This unique organization allows mammalian
cells to store large amounts of carbohydrate energy in a soluble
rapidly accessible form. Without branching, glucose polymers 13
units or longer are poorly soluble and tend to precipitate and
crystallize [8]. Polyglucosans are malformed glycogen molecules.
They have very long chains, insufficient branches, and a resultant
lack of spherical organization. They are more similar to plant
amylopectin or starch than to glycogen, and like these plant
carbohydrates they are insoluble, precipitate, and accumulate
[3,5,9].
Glycogen is synthesized through coordinated actions of
glycogen synthase (GS) and glycogen branching enzyme, the
former responsible for chain elongation, the latter for chain
branching. Glycogen is digested by glycogen phosphorylase (GP)
and glycogen debranching enzyme. PTG (protein targeting to
glycogen) is an indirect activator of GS and an indirect inhibitor
of both GP and glycogen phosphorylase kinase (GPK), the
enzyme that activates GP. PTG performs this reciprocal
activation of synthesis and inhibition of breakdown by binding
the pleiotropic phosphatase PP1 through its C-terminus, binding
glycogen, and through a common region in its N-terminus (amino
acid sequence WDNNE) binding GS, GP, or GPK, thus targeting
PP1 to each of the three enzymes. PP1 dephosphorylates each of
the three enzymes, activating GS and inhibiting GP and GPK
[10,11].
There are two main hypotheses of polyglucosan formation, the
first based on evidence from cell models that laforin interacts with
malin and with PTG, and that the laforin-malin complex
downregulates GS through malin-mediated ubiquitination and
degradation of PTG. In this hypothesis, absence of laforin or malin
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excessive extension of glycogen chains and conversion of glycogen
to polyglucosan [12–14]. Although results from animal models
have yet to confirm this idea [15–17], there is indeed a body of
work implicating PTG.
The second hypothesis is based on the observation that laforin
dephosphorylates glycogen and that in LD there is progressive
hyperphosphorylation of glycogen, causing it to unfold and
precipitate. GS remains bound to the precipitating glycogen, but
glycogen branching enzyme, the enzyme responsible for
branching, even under normal condition does not associate
tightly [16–19]. In this hypothesis, elongation by GS of the
chains of the precipitated glycogen, with no branching, would
convert glycogen to polyglucosan. Both hypotheses predict that
inhibiting GS would prevent polyglucosan formation, and if LB
are causative of the PME, this might ameliorate or cure the
epilepsy. One way to inhibit GS would be to interfere with its
activation by PTG. In the present work we genetically remove
PTG from mice with LD. We obtain dramatic reduction in LB,
and resolution of neurodegeneration and the PME. This work
has direct implications for therapeutic intervention in this fatal
disease.
Results
Generation of laforin-deficient mice lacking PTG
We initially considered removing the muscle/brain isoform of
GS (GYS1) from LD mice by breeding GYS1-deficient mice with
laforin-deficient mice. However, this is impractical because in
90% of cases GYS1-deficient mice cannot survive birth (although
the 10% that do are subsequently healthy with normal lifespan
and exercise tolerance) [20,21]. Recently, DePaoli-Roach gener-
ated a mouse line deficient of PTG. In contrast to an earlier
report that disruption of the PTG gene was embryonic lethal
[22], the present mice are healthy and have normal lifespan [23].
Their glycogen is reduced by 30% in skeletal muscle and by 70%
in brain.
Laforin-deficient mice (LKO) have been extensively character-
ized and exhibit LB formation, neurodegeneration, and PME [24].
The PME is not as severe as in humans. The mice develop
progressively worsening myoclonus, but convulsive seizures are not
seen [24]. Unlike human patients and despite the neurodegener-
ative changes and progressive myoclonus LKO mice do not have a
shortened lifespan (unpublished observation). Metabolically, LKO
mice have progressively increasing accumulation of glycogen in
tissues, reaching approximately fivefold normal in brain and
threefold in skeletal muscle by age nine to 12 months [16]. To
remove PTG from the laforin-deficient mice, we bred LKO mice
with PTG knockout mice and interbred their litters to produce
PTG/laforin double knockout (DKO) animals. DKO mice are
born at Mendelian frequency, have normal skin, body habitus and
growth, exhibit no obvious behavioral abnormalities, and appear
to have normal lifespan, our oldest presently healthy at 18 months
of age.
Laforin-deficient mice lacking PTG have greatly
decreased Lafora bodies and normal glycogen levels
As mentioned, nine to 12 month-old LKO mice have vast
amounts of LB in brain and other organs, and neurodegeneration
[24]. We studied brain and skeletal muscle from LKO and DKO
mice and their wild-type (wt) littermates at 12 months and found
massive reduction in LB in DKO mice (Figure 1 and Figure 2). In
hippocampus, frontal cortex and cerebellum, the numbers of LB
in neuronal processes in DKO were respectively 3%, 0.1%, and
0.5% of those in LKO animals. The numbers of perikaryal LB
were diminished to 10% in hippocampus and 5% in frontal
cortex. In cerebellum, perikaryal LB were not significantly
reduced in number, although they were much smaller in size.
In skeletal muscle, LB had completely disappeared, compared to
their very large quantities in LKO animals (Figure 3). Wt
animals, as expected, had no LB in either tissue. To determine
whether the reductions in LB correlated with reductions in
glycogen content, we measured total glycogen in whole brain and
skeletal muscle and found that the increased glycogen content of
LKO mice had normalized to wt levels in DKO animals
(Figure 4).
Absence of PTG rescues neurodegeneration in
laforin-deficient mice
Lost neurons are replaced by astrocytes. We assessed
neuronal loss in DKO, LKO and wt animals at 12 months
first by measuring gliosis, which we quantified by morphometric
counts of glial fibrillary acidic protein (GFAP)-positive cells. In
cerebellum, there were no differences between the genotypes. In
hippocampus and frontal cortex, however, DKO mice had half
the number of astrocytes as LKO animals, and the same
number as wt, i.e., they have no measurable gliosis (Figure 5).
We next assessed neurodegeneration directly. In their original
study of neuropathology in LKO mice, Ganesh and colleagues
noted absence of apoptosis and necrosis. Using electron
microscopy (EM), they documented an unusual form of somatic
degeneration characterized chiefly by shrinkage and retraction
of plasma and nuclear membranes and darkening of the
cytoplasm [24]. We performed EM studies in the present set
of LKO, DKO and wt mice. Figure 6A–6C show representative
wt cerebellar Purkinje neurons with characteristic full nuclei and
cytoplasms and taut and circular plasma membranes. Numerous
axon terminals are seen directly apposed to the membranes
Author Summary
Lafora disease (LD) is a fatal epilepsy that afflicts
previously normal teenagers. It is caused by mutations
in the EPM2A or EPM2B genes encoding the laforin
carbohydrate-binding phosphatase and the malin E3
ubiquitin ligase. LD is the most common neurodegen-
erative epilepsy of adolescents. Affected children suffer
an ordeal lasting 10 years, consisting of escalating
seizures, constant body jerking, particularly frightening
epileptic visual hallucinations, and later on dementia.
They die of massive convulsion. Brain biopsies reveal
accumulation of a starch-like compound, polyglucosan,
overtaking dendrites and likely causing the disease, and
neurodegeneration. Glycogen synthase (GS), the enzyme
that forms normal glycogen, is also responsible for
synthesizing these polyglucosans. We reasoned that
reducing GS activity might prevent polyglucosan forma-
tion. Mice deficient of Epm2a replicate LD and are a
standard model. Members of our group generated mice
deficient of PTG, a protein involved in activating GS. By
breeding LD mice with PTG-lacking mice, we generated
LD mice lacking the GS-activating effect of PTG. This
resulted in a cure. The double knockout mice have
almost no polyglucosan, no neurodegeneration, and no
seizures. Our work opens an avenue of treatment for this
fatal epilepsy, which may also be applicable to other
glycogen storage diseases.
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circumferences of the cells. Figure 6D–6F show typical LKO
Purkinje cells. Nucleus and cytoplasm are shrunken. The plasma
membrane is wrinkled and retracted with appearance of
indistinct spaces between it and the axon boutons that would
normally associate with it, effectively resulting in loss of synaptic
contacts. Numerous LB in neuronal processes are present.
Figure 6G–6I show representative DKO Purkinje cells. The
cells are essentially back to normal with full nuclei and
cytoplasms, circular plasma membranes, and generally a full
complement of synapses around the cell body. However, the
correction while near-perfect is not completely perfect. The
plasma membrane is not quite as taut as in wt, and there are
rare instances of synaptic contact loss.
Absence of PTG rescues the myoclonus of
laforin-deficient mice
Myoclonus is a single jerk of the body or of a body part. Mice,
like humans, exhibit a certain amount of physiologic myoclonus,
such as hypnagogic myoclonus [25,26]. In LD patients,
myoclonus is extremely frequent and in later stages near-constant
and debilitating [4,5,25]. We counted myoclonus in 12 month-
old wt, LKO, and DKO animals, blind to genotype. Myoclonus
was defined as sudden rapid jerks of the head or of the dorsum of
Figure 1. LB in brain of 12 month-old LKO and DKO mice. (a–b) Frontal cortex and hippocampus respectively from a LKO mouse stained with
PAS-D. Note abundant LB within the neuropil and in the perikarya of numerous neurons. (c–d) Comparable regions from a DKO mouse. Arrows,
examples of LB. All bars, 50 mm.
doi:10.1371/journal.pgen.1002037.g001
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retropulsion of the animal, closely resembling the myoclonus we
documented previously in canine LD [27]. LKO mice have
fourfold increased myoclonus over wt. DKO were the same as wt
(Figure 7). In their original description Ganesh and colleagues
reported that in addition to myoclonus 80% of nine to 12 month-
old LKO animals also exhibit myoclonic seizures (polymyoclo-
nus), consisting of rapid repetitive head and body jerks lasting few
seconds and associated with epileptic discharges on electrocorti-
cography [24]. We observed polymyoclonus in 80% of the
present 12 month-old LKO mice, in no wt mice, and in no DKO
mice.
Discussion
In this study we show for the first time that removal of PTG
in an animal model of LD reduces LB formation, and
eliminates neuronal loss and the myoclonic epilepsy. PTG is
not the only protein that targets PP1 to glycogen and glycogen
metabolizing enzymes. Others include R6, which like PTG is
ubiquitously expressed, RGL/GM specific to striated muscle,
and GL found in rodent liver [7,28]. It is therefore not
surprising that skeletal muscle and brain of PTG-deficient mice
still make glycogen, 70% and 30% of normal respectively [23].
What is surprising is the complete absence of LB in skeletal
muscle in DKO. It would have been expected that if there is
70% glycogen synthesis in the absence of PTG, there would be
70% LB formation in the absence of laforin and PTG. Possibly,
LB formation requires a threshold amount of glycogen.
Alternatively, the laforin-malin complex in skeletal muscle
acts specifically through PTG. On the other hand, if PTG is
the preferred mediator of laforin-malin, it is surprising that its
elimination from brain results in incomplete disappearance of
LB, despite deeper glycogen reduction in brain in PTG
deficient mice than in muscle. Much work ahead is needed
to resolve these paradoxes.
The cause of neurodegeneration in LD has received much
attention in recent years. Presence of up to 28% protein in some
LB [9,29], and signs of neurodegeneration in LKO mice at two
months of age when LB are still small [24], led to considerations as
Figure 2. LB numbers in brain. (a) Morphometric analysis of granular LB in whole brain and different brain regions. Granular is the histochemical
description of the small LB in the neuropil, which by electron microscopy are shown to be in neuronal processes, mainly dendrites. Statistics: p,0.001
in all regions between LKO and DKO (ANOVA); n=4 per genotype. (b) Morphometric analysis of perikaryal LB. Statistics: p,0.001 between LKO and
DKO, except in cerebellum, where the difference is not significant (ANOVA); n=4 per genotype.
doi:10.1371/journal.pgen.1002037.g002
Figure 3. LB in skeletal muscle. (a) Muscle from a LKO mouse stained with PAS-D. Note presence of numerous LB in many fibers; bar, 100 mm;
arrows, LB-replete myofibers; arrowheads, myofibers not containing LB. (b) Comparable field from a DKO mouse; bar, 50 mm. Higher magnification
chosen for the DKO example to illustrate lack of even small LB.
doi:10.1371/journal.pgen.1002037.g003
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but to protein aggregation, similar to Alzheimer’s and other
neurodegenerative diseases [24,30–32]. In the present study,
correction of the neurodegeneration through interference in
glycogen metabolism suggests that the neurodegeneration is
connected to the disturbance in glycogen metabolism. This is
consistent with recent observations that neurons, unlike other cell
types, are highly vulnerable to increases in glycogen and
polyglucosan content, with upregulation of GS leading to cell
death [13]. Presence of small LB in two month-old LKO mice
indicates that polyglucosans were already formed and accumulat-
ing by that time, likely triggering cell death, even as they had not
yet formed large LB. Proteins in LB could be glycogen-
metabolizing and other proteins trapped amidst aggregating
polyglucosans.
Recently, it was reported that laforin enhances macroautophagy
and that macroautophagy is dysfunctional in LD [33], indicating
that laforin might function not only to prevent polyglucosan
formation but also in clearing polyglucosans when they do form.
Our results show that preventing polyglucosan formation obviates
other laforin functions and suffices to prevent LD in mouse.
A major question in LD is why this particular neurode-
generative disease exhibits extremely severe epilepsy. Poly-
glucosans and LB occur in one other neurological disease,
Adult Polyglucosan Body Disease (APBD), caused by muta-
tions in the glycogen branching enzyme gene [34]. APBD LB
differ from LD LB in one respect. For reasons unknown, they
form exclusively in axons, especially long axons traveling to
and from peripheral structures (skin, muscle, etc.) and the
central nervous system. Affected patients suffer from motor
neuron disease, may have mild dementia, but have no
epilepsy [34,35]. LD LB, on the other hand, are not seen in
long tract axons, but instead almost completely replace the
cytoplasm of vast numbers of small neuronal processes,
mainly dendrites [3,5,6]. One possibility for the intractable
epilepsy in LD is the progressive disturbance of dendritic
function, the chief determinant of a neuron’s excitability state.
Near-complete disappearance of dendritic LB in the present
study may account for the correction of the PME in our DKO
mice.
In this paper, we correct the pathology and eliminate the PME
of LD through genetic depletion of one of the proteins that
targets the PP1 phosphatase to glycogen and the glycogen
metabolizing enzymes. The effect on glycogen is partial, i.e.
glycogen is not altogether eliminated, only reduced, the reduction
returning the elevated glycogen levels of LD to normal wt levels,
correcting the cardinal features of the disease, and causing no
apparent harm to the mice. The crystal structures of PP1 [36],
GS [37,38], GP [39,40], and GPK [41] are known, as is the PTG
interaction domain with GS, GP and GPK [10,12]. Identification
of inhibitors of this interaction through rational design or large-
scale small molecule screens could result in a treatment for this
fatal epilepsy.
In addition to LD, accumulation of normal or abnormal
glycogen is a cause of disease in several glycogen storage diseases
including APBD and its severe fatal infantile form Andersen’s
disease [42], and the common and debilitating glycogenosis
Pompe disease (acid maltase deficiency) [43]. Our results in LD
suggest that removal of PTG could also improve these diseases. In
fact, GS itself was recently removed from a Pompe mouse model
resulting in a cure of the disease in that model [44]. While
complete elimination of GS in humans cannot be contemplated as
this causes significant pathology including sudden cardiac death
[45], the Pompe study and our present work suggest that classes of
medications that partially reduce GS or that partially reduce GS
and activate GP, e.g. through interference in the PTG – GS/GP/
GPK interaction, could have therapeutic benefit in multiple
glycogenoses.
Methods
Ethics statement
All animal procedures were approved by the Toronto Centre
for Phenogenomics Animal Care Committee.
Immunohistochemical staining
Laforin-deficient mice were a gift of Dr. AV Delgado-Escueta
and S Ganesh. Mice were sacrificed by cervical dislocation and
tissues immediately fixed in 10% formalin. Periodic acid-Schiff-
diastase (PAS-D) staining was as previously described [17]. PAS
stains normal glycogen and polyglucosans. The short treatment
with diastase (amylase) digests glycogen but not polyglucosans.
Diastase resistant PAS stained structures are LB. For GFAP
staining, deparaffinized 5 mm sections were incubated with a
polyclonal GFAP antibody (Dako) for one hour. Sections were
thoroughly rinsed, and antibody visualized using diaminobenzi-
dine conjugated avidin biotin complex (Vector).
Figure 4. Glycogen levels in skeletal muscle and brain in 12-
month-old wt, LKO, and DKO mice (mmol glucose/gm tissue).
Skeletal muscle (a) and brain (b).
doi:10.1371/journal.pgen.1002037.g004
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Images from PAS-D slides were acquired at a 4006
magnification (Olympus) by a CCD camera (Roper Scientific).
Perikaryal and granular (neuronal processes) LB were distin-
guished by size and location. Numerical density [46] of both
perikaryal and granular LB was then determined using the
formula:
N~
either NpLBa or NgLBa
4=p ðÞ :d ðÞ zt{2h
where N is the number of either the perikaryal LB or the number
of granular LB per unit volume of tissue (number/mm
3), NpLBa is
the number of perikaryal LB per area, NgLBa is the number of
granular LB per area, d is the average diameter of either the
perikaryal or granular LB, t is the thickness of the section (5 mm),
and h is the smallest recognizable LB (1 mm). A minimum of 500
fields/animal were analyzed using an image analysis program
(Image Pro Plus, Media Cybernetics, Bethesda). Data were
expressed as means 6 SEM and significance calculated using an
ANOVA analysis.
Astrocyte counts
Images from GFAP stained slides were acquired at a 2506
magnification using the same microscope and equipment as above.
The total number of GFAP positive cells was divided by the total
area and expressed as cells/mm
2. Genotype was blinded to the
reviewer. A minimum of 250 fields/animal were analyzed. Images
Figure 5. Gliosis in LKO mice. (a) Hippocampus of a LKO mouse stained with GFAP. Note the large numbers of GFAP-positive astrocytes. (b)
Comparable region from a DKO mouse. Bars, 100 mm. Arrows, astrocytes; arrowheads, gliosis. (c) Counts of GFAP-positive astrocytes. For significance,
whole brain p,0.02; hippocampus p,0.001; cerebellum, not significant; frontal cortex, p,0.002 (ANOVA); n=4–7 per genotype.
doi:10.1371/journal.pgen.1002037.g005
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Bethesda). Data were expressed as means 6 SEM and significance
calculated using ANOVA.
Glycogen measurements
Mice were sacrificed by cervical dislocation and tissues quickly
frozen in liquid nitrogen. Tissues were ground with a mortar and pestle
in liquid nitrogen.Aliquots of30–50 mg oftissue were mixed with 30%
potassium hydroxide (KOH) and boiled at 100uCw i t hf r e q u e n t
mixing. Glycogen was then precipitated with a final concentration of
67% ethanol at 220uC, then pelleted. This process was repeated three
times.The purified glycogen sampleswere then dried and suspended in
sodium acetate buffer. Glycogen was digested with amyloglucosidase
(Sigma) at 37uC. Released glucose was determined using a glucose
assay kit (Sigma). The amount of glycogen was calculated and
expressed as mmoles of glucose per gram of tissue.
Figure 6. Neurodegeneration in LKO mice. (a–c) Cerebellar Purkinje cells from a wt mouse. Note the smooth appearance of the plasma
membrane and the absence of any voids between the cell and the surrounding neuronal processes; N, nucleus; arrows, synapses. (d) Purkinje cell
from a LKO mouse. Numerous LBs are seen surrounding the cell (asterisks). (e) Higher power of an LKO Purkinje cell; arrows indicate wrinkling and
retraction of plasma membrane. (f) A large LB (asterisk) in close proximity to a degenerating LKO Purkinje cell. (g) A typical DKO Purkinje cell. Note its
full normal appearance and smooth plasma membrane. Part of a second normal Purkinje cell is seen to the right of the panel. (h) Higher power of
plasma membrane from a DKO Purkinje cell. Note the relative linear appearance of the membrane and the attached synapses (arrows) typical of a
normal cell. (i) One of few LB (asterisk) near Purkinje cells detected by EM in DKO.
doi:10.1371/journal.pgen.1002037.g006
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Brains for electron microscopy were taken from mice first
perfused through the left ventricle of the heart with 2.5%
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). The tissue
was minced into cubic 1 mm blocks and fixed for an additional
two to four hours. Samples were then washed in buffer and post
fixed in phosphate-buffered 2% OsO4 for one hour. They were
then dehydrated in an ascending series of acetones prior to being
infiltrated, embedded and polymerized at 60uC overnight in
embed 812-Araldite. Ultrathin sections were then prepared and
stained with uranyl acetate and lead citrate prior to examination
and image acquisition in the EM (JEOL JEM 1011, Peabody,
MA).
Myoclonus measurements
Mice were placed in individual Plexiglas chambers and
videotaped for four hours. Myoclonus was counted during periods
when the animal was not exploring. Myoclonus counts were
obtained in periods of a minimum of 10 minutes per mouse. The
entire record was reviewed for detection of polymyoclonus.
Observer was blinded to genotype. Myoclonus data in Figure 7
is shown as means 6 SEM and significance calculated using an
unpaired student’s t-test.
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